Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer
Authors Zhu S, Jiang LL, Wang LY, Wang LL, Zhang C, Ma Y, Huang T
Received 7 July 2018
Accepted for publication 16 November 2018
Published 3 January 2019 Volume 2019:11 Pages 419—430
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Rituraj Purohit
Sha Zhu,1 Lili Jiang,1,2 Liuyan Wang,3 Lingli Wang,1 Cong Zhang,1 Yu Ma,1 Tao Huang4
1Department of Immunology, Collaborative Innovation Center of Cancer Chemoprevention, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; 2Department of Basic Medicine, School of Nursing, Zhengzhou University, Zhengzhou, Henan, China; 3Department of Medicine, The Third People’s Hospital of Zhengzhou, Zhengzhou, Henan, China; 4Oncological Surgery, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China
Background: Resistance to mitoxantrone (MTX), an anthracenedione antineoplastic agent used in advanced and metastatic androgen-refractory prostate cancer (PCa), seriously limits therapeutic success.
Methods: Xenografts from two human PCa cell lines (VCaP and CWR22) were established in male severe combined immunodeficiency mice, and MTX was administered, with or without concurrent castration, three times a week until tumors relapsed. Microarray technology was used to screen for differentially expressed genes (DEGs) in androgen-independent, MTX-resistant PCa xenografts. Gene expression proﬁles of MTX-treatment xenografts and their respective parental cell lines were performed using an Agilent whole human genome oligonucleotide microarray and analyzed using Ingenuity Pathway Analysis software.
Results: A total of 636 genes were differentially expressed (fold change ≥1.5; P<0.05) in MTX-resistant castration-resistant prostate cancer (CRPC) xenografts. Of these, 18 were selected to be validated and showed that most of these genes exhibited a transcriptional profile similar to that seen in the microarray (Pearson’s r=0.87). Western blotting conducted with a subset of genes deregulated in MTX-resistant CRPC tumors was shown through network analysis to be involved in androgen synthesis, drug efflux, ATP synthesis, and vascularization.
Conclusion: The present data provide insight into the genetic alterations underlying MTX resistance in androgen-independent PCa and highlight potential targets to improve therapeutic outcomes.
Keywords: castration-resistant prostate cancer, gene expression profiling, drug resistance, differentially expressed genes
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]